Can Medications Delay or Replace Colon Surgery for FAP?
At a Glance
In FAP, medicines such as sulindac or celecoxib may temporarily reduce polyp number or size, but they do not reliably prevent colorectal cancer or replace preventive surgery. A carefully monitored delay may be possible for selected people with attenuated FAP or a manageable polyp burden.
In this answer
4 sections
When you are diagnosed with Familial Adenomatous Polyposis (FAP), the prospect of having preventive colon surgery (colectomy) can be daunting. It is completely natural to wonder if there is a medication, supplement, or alternative approach that can shrink the polyps enough to help you avoid surgery entirely.
While certain prescription medications can help manage polyps, no medication, supplement, or alternative therapy has been proven to safely replace the need for eventual preventive colon surgery in classic FAP [1][2]. Because classic FAP carries a near 100% lifetime risk of colorectal cancer if left untreated, prophylactic (preventive) surgery remains the standard of care to markedly reduce your risk [3][4].
The Role of Chemoprevention
Using medications to lower the risk of cancer or slow the growth of polyps is called chemoprevention. The most commonly studied medications for FAP are nonsteroidal anti-inflammatory drugs (NSAIDs) such as sulindac and celecoxib [1]. Do not start taking over-the-counter NSAIDs (like aspirin or ibuprofen) or supplements to treat your FAP without specialist guidance, as these require medical supervision [5].
In some patients, these prescription medications have been shown to reduce the number of polyps or shrink their size [6]. However, the research shows important limitations to this approach:
- The effect is temporary and incomplete: Medications may slow polyp growth, but they do not eliminate the polyps completely or stop new ones from forming [7][8].
- They do not reliably prevent cancer: Adenoma reduction has not been proven to produce durable colorectal cancer prevention sufficient to replace surgery or surveillance [3][1].
- Long-term results are mixed: Clinical trials have struggled to prove that these medications significantly delay the overall progression of the disease or the ultimate need for major surgery [9].
Can Surgery Be Safely Delayed?
In specific, carefully selected cases—such as patients with a milder form of the disease (attenuated FAP) or those with a manageable polyp burden (the total number and size of polyps)—doctors may consider temporarily postponing surgery [10]. Some patients with attenuated FAP can be managed for prolonged periods this way, whereas classic FAP usually requires earlier surgery [11].
Delaying surgery requires a rigorous, intensive commitment to individualized endoscopic surveillance. This means:
- Undergoing frequent colonoscopies to monitor the colon and clear polyps. The interval is set by your specialist and may be shorter than standard guidelines depending on how hard the polyps are to control [12].
- Having larger polyps removed endoscopically during these procedures. The exact size threshold for removal is individualized by your doctor based on clinical findings [13].
Even with this intensive monitoring, surgery is typically needed once the polyps become too numerous to clear, grow too large to be safely removed during a colonoscopy, or if there are signs of high-grade dysplasia (advanced precancerous cell changes that increase the urgency of surgery) [13][11].
Weighing the Risks of Medication
Taking NSAIDs like sulindac or celecoxib long-term is not without risk, and they are not appropriate for everyone. Long-term or high-dose use of these medications can increase the risk of:
- Gastrointestinal bleeding or ulcers [14].
- Kidney damage or changes in kidney function [15].
- Cardiovascular issues, including increased blood pressure, heart attack, stroke, and fluid retention [15][5].
- Uncommon liver abnormalities [16].
It is vital to review your full medical history with your doctor, especially if you have a history of ulcers, kidney disease, cardiovascular disease, uncontrolled blood pressure, or if you take anticoagulants (blood thinners) [5]. If you experience severe abdominal pain, vomiting, chest pain, or noticeable bleeding while on these medications, seek urgent medical care.
Moving Forward: Surgical Options and Beyond
If surgery is indicated, it is not a “one size fits all” procedure. Your surgical and gastroenterology team will look at factors like the number and location of your polyps, your genetic mutation, and your personal needs to recommend an individualized approach [17][18]. Options often include:
- Total colectomy with ileorectal anastomosis: Removing the colon but leaving the rectum, which may be an option if your rectal polyp burden is low [19].
- Proctocolectomy: Removing both the colon and rectum, which can be followed by creating an internal pouch (ileal pouch-anal anastomosis) or an external stoma (end ileostomy) [19].
Surgery Reduces Risk, But Does Not End Care
It is crucial to understand that surgery does not cure FAP or end the need for medical care [20]. Even after surgery, you will require lifelong surveillance. Polyps can still develop in a retained rectum or ileal pouch, and FAP causes an increased risk of polyps and cancer in the upper digestive tract (like the duodenum), requiring separate upper-GI endoscopies [20][21].
Common questions in this guide
Can sulindac or celecoxib replace preventive colon surgery in FAP?
When might someone with FAP postpone surgery?
What would intensive surveillance involve if FAP surgery is delayed?
What are the risks of taking NSAIDs for FAP over the long term?
What types of surgery are used for FAP?
Will I still need monitoring after FAP surgery?
Related questions
Show more
Get notified when new evidence is published on Familial Adenomatous Polyposis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM, Mankaney G, Vreeland TJ, et al.
Familial cancer 2021; (20(1)):23-33 doi:10.1007/s10689-020-00189-y.
PMID: 32507936 - 2
Chemoprevention Considerations in Patients with Hereditary Colorectal Cancer Syndromes.
Macaron C, Mankaney GN, Haider M, et al.
Gastrointestinal endoscopy clinics of North America 2022; (32(1)):131-146 doi:10.1016/j.giec.2021.08.005.
PMID: 34798982 - 3
American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes.
Yang J, Gurudu SR, Koptiuch C, et al.
Gastrointestinal endoscopy 2020; (91(5)):963-982.e2 doi:10.1016/j.gie.2020.01.028.
PMID: 32169282 - 4
The importance of genetics for timing and extent of surgery in inherited colorectal cancer syndromes.
Aoun RJN, Kalady MF
Surgical oncology 2022; (43()):101765 doi:10.1016/j.suronc.2022.101765.
PMID: 35643746 - 5
Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations.
Szeto CC, Sugano K, Wang JG, et al.
Gut 2020; (69(4)):617-629 doi:10.1136/gutjnl-2019-319300.
PMID: 31937550 - 6
Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis.
Yang P, Zuo X, Advani S, et al.
Cancer prevention research (Philadelphia, Pa.) 2022; (15(4)):217-223 doi:10.1158/1940-6207.CAPR-21-0066.
PMID: 34610992 - 7
Chemoprevention of familial adenomatous polyposis.
Lynch PM
Familial cancer 2016; (15(3)):467-75 doi:10.1007/s10689-016-9901-9.
PMID: 27083160 - 8
[Clinical and molecular characteristics of a child with familial adenomatous polyposis].
Zhang J, Li Z, Huang X, Ye J
Zhonghua er ke za zhi = Chinese journal of pediatrics 2016; (54(3)):205-8 doi:10.3760/cma.j.issn.0578-1310.2016.03.010.
PMID: 26957067 - 9
Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
Burke CA, Dekker E, Lynch P, et al.
The New England journal of medicine 2020; (383(11)):1028-1039 doi:10.1056/NEJMoa1916063.
PMID: 32905675 - 10
Intensive endoscopic resection for downstaging of polyp burden in patients with familial adenomatous polyposis (J-FAPP Study III): a multicenter prospective interventional study.
Ishikawa H, Yamada M, Sato Y, et al.
Endoscopy 2023; (55(4)):344-352 doi:10.1055/a-1945-9120.
PMID: 36216266 - 11
Web-Based Model for Predicting Time to Surgery in Young Patients with Familial Adenomatous Polyposis: An Internally Validated Study.
Sarvepalli S, Burke CA, Monachese M, et al.
The American journal of gastroenterology 2018; (113(12)):1881-1890 doi:10.1038/s41395-018-0278-2.
PMID: 30333551 - 12
Endoscopic management of familial adenomatous polyposis targeting colorectal lesions greater than 5 mm in size: a single-center retrospective study.
Murano T, Ikematsu H, Shinmura K, et al.
Familial cancer 2023; (22(1)):83-89 doi:10.1007/s10689-022-00308-x.
PMID: 35930210 - 13
Optimizing the timing of colorectal surgery in patients with familial adenomatous polyposis in clinical practice.
Vasen HFA, Ghorbanoghli Z, de Ruijter B, et al.
Scandinavian journal of gastroenterology 2019; (54(6)):733-739 doi:10.1080/00365521.2019.1621930.
PMID: 31401889 - 14
Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review.
Beaudart C, Brabant C, Alokail M, et al.
Drugs 2025; (85(10)):1289-1306 doi:10.1007/s40265-025-02234-5.
PMID: 40911151 - 15
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Obeid S, Libby P, Husni E, et al.
European heart journal. Cardiovascular pharmacotherapy 2022; (8(6)):611-621 doi:10.1093/ehjcvp/pvac015.
PMID: 35234840 - 16
Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials.
Sriuttha P, Sirichanchuen B, Permsuwan U
International journal of hepatology 2018; (2018()):5253623 doi:10.1155/2018/5253623.
PMID: 29568654 - 17
Dispelling misconceptions in the management of familial adenomatous polyposis.
Chittleborough TJ, Warrier SK, Heriot AG, et al.
ANZ journal of surgery 2017; (87(6)):441-445 doi:10.1111/ans.13919.
PMID: 28266097 - 18
Association between the age and the development of colorectal cancer in patients with familial adenomatous polyposis: a multi-institutional study.
Kobayashi H, Ishida H, Ueno H, et al.
Surgery today 2017; (47(4)):470-475 doi:10.1007/s00595-016-1398-1.
PMID: 27506752 - 19
Surgical Decision-Making in Familial Adenomatous Polyposis.
Steinberger AE, Westfal ML, Wise PE
Clinics in colon and rectal surgery 2024; (37(3)):191-197 doi:10.1055/s-0043-1770732.
PMID: 38617844 - 20
Management of familial adenomatous polyposis and MUTYH-associated polyposis; new insights.
Aelvoet AS, Buttitta F, Ricciardiello L, Dekker E
Best practice & research. Clinical gastroenterology 2022; (58-59()):101793 doi:10.1016/j.bpg.2022.101793.
PMID: 35988966 - 21
Updated Perspectives on the Diagnosis and Management of Familial Adenomatous Polyposis.
Kyriakidis F, Kogias D, Venou TM, et al.
The application of clinical genetics 2023; (16()):139-153 doi:10.2147/TACG.S372241.
PMID: 37600856
This page explains medication, surveillance, and preventive surgery decisions in FAP for informational purposes only and does not constitute medical advice. Discuss your individual timing and treatment options with your gastroenterologist and colorectal surgeon.